The Lancet September 12, 1998

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

UK Prospective Diabetes Study (UKPDS) Group

Bottom Line

In newly diagnosed patients with type 2 diabetes, intensive blood-glucose control with sulfonylureas or insulin significantly reduced the risk of microvascular complications compared to conventional diet-based therapy, without increasing cardiovascular mortality.

Key Findings

1. Over a median follow-up of 10 years, intensive therapy achieved a median HbA1c of 7.0%, compared with 7.9% in the conventional group (an 11% relative reduction).

2. Intensive control reduced the risk of 'any diabetes-related endpoint' by 12% compared to conventional treatment (95% CI 1-21, p=0.029).

3. The benefit in the aggregate endpoint was predominantly driven by a 25% risk reduction in microvascular complications (95% CI 7-40, p=0.0099), including the need for retinal photocoagulation.

4. There was a 16% reduction in the risk of myocardial infarction in the intensive group, which was of borderline statistical significance (p=0.052).

5. There was no significant difference in diabetes-related death (10% reduction, p=0.34) or all-cause mortality (6% reduction, p=0.44) between the groups during the trial period.

6. Major hypoglycemic episodes per year were more frequent with intensive control: 0.7% with conventional treatment, 1.0% with chlorpropamide, 1.4% with glibenclamide, and 1.8% with insulin (p<0.0001).

7. Patients in the intensive group had significantly greater weight gain than the conventional group (mean difference of +2.9 kg, p<0.001), with insulin causing the greatest gain (+4.0 kg).

Study Design

Design

Randomized Controlled Trial

Open-Label

Sample

3,867

Patients

Duration

10 yr

Median

Setting

Multicenter, UK

Population Newly diagnosed type 2 diabetes patients, median age 54 years, with a mean fasting plasma glucose of 6.1-15.0 mmol/L after 3 months of diet therapy.

Intervention Intensive blood-glucose control with a sulfonylurea (chlorpropamide, glibenclamide, or glipizide) or insulin (targeting fasting plasma glucose <6.0 mmol/L).

Comparator Conventional treatment primarily with diet alone (pharmacotherapy added only for hyperglycemic symptoms or fasting plasma glucose >15.0 mmol/L).

Outcome Three aggregate endpoints: any diabetes-related endpoint, diabetes-related death, and all-cause mortality.

Study Limitations

• The open-label nature of the trial could introduce reporting bias for subjective endpoints, although major clinical endpoints were objectively measured.

• Because type 2 diabetes is a progressive disease with declining beta-cell function, patients in the conventional group often required pharmacological rescue therapy, narrowing the glycemic separation between the groups to a median HbA1c difference of only 0.9%.

• The trial was underpowered to definitively confirm the 16% reduction in myocardial infarction during the primary follow-up period, leaving some initial ambiguity regarding macrovascular benefit.

• The complex, evolving 20-year trial protocol included parallel sub-studies (such as the addition of metformin in overweight patients in UKPDS 34), making the interpretation of isolated interventions challenging.

Clinical Significance

UKPDS 33 is a foundational pillar of modern diabetology. It definitively proved that the microvascular complications of type 2 diabetes are directly linked to hyperglycemia and can be prevented by intensive glycemic control. It also fundamentally demonstrated the progressive nature of type 2 diabetes, showing that monotherapy inevitably fails over time and stepwise escalation is required. Furthermore, it reassured the medical community that insulin and sulfonylureas do not cause cardiovascular harm, dispelling decades of anxiety and establishing an HbA1c target of ~7.0% as the standard of care for most newly diagnosed patients.

Historical Context

Prior to the UKPDS, the controversial University Group Diabetes Program (UGDP) trial in the 1970s suggested that sulfonylureas increased cardiovascular mortality, causing widespread hesitance to aggressively treat type 2 diabetes with pharmacotherapy. While the DCCT (1993) proved that intensive glucose control prevented microvascular complications in type 1 diabetes, type 2 diabetes was viewed as a different pathophysiologic entity driven by insulin resistance, where macrovascular disease was the primary concern. UKPDS 33, running for 20 years, silenced the debate by proving that intensive control prevents microvascular disease in T2DM without increasing cardiovascular risk. A subsequent 10-year post-trial follow-up published in 2008 ultimately revealed a 'legacy effect,' showing that early intensive control translated to significant long-term reductions in myocardial infarction and all-cause mortality.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why does intensive blood glucose control with sulfonylureas or insulin primarily reduce microvascular complications like retinopathy and nephropathy, but have a less pronounced immediate effect on macrovascular complications like myocardial infarction?

Key Response

Microvascular damage in diabetes is directly driven by hyperglycemia-induced endothelial toxicity via pathways like advanced glycation end-products and the polyol pathway. In contrast, macrovascular disease is multifactorial and heavily influenced by dyslipidemia, hypertension, and inflammation, explaining why glucose control alone is insufficient to prevent it in the short term.

Resident

Given the UKPDS 33 findings that intensive control with insulin or sulfonylureas increases the risk of weight gain and severe hypoglycemia, how should you individualize glycemic targets for a newly diagnosed 75-year-old patient with type 2 diabetes and a history of falls?

Key Response

While UKPDS established the benefit of lower HbA1c for microvascular protection, clinicians must balance this against the harms of hypoglycemia. In older patients with fall risks, the severe consequences of hypoglycemia (fractures, head trauma) often outweigh the long-term microvascular benefits, prompting a less stringent HbA1c target (e.g., 7.5-8.0%) and avoidance of sulfonylureas.

Fellow

UKPDS 33 initially showed no significant reduction in macrovascular outcomes with intensive control, but the 10-year post-trial monitoring (UKPDS 80) revealed a delayed macrovascular benefit. What is the physiological mechanism behind this 'metabolic memory' or legacy effect, and how does it influence the urgency of early endocrinology intervention?

Key Response

'Metabolic memory' suggests that early glycemic control prevents long-lasting epigenetic changes and oxidative stress pathways in the vasculature. For specialists, this emphasizes the critical window of early intervention in newly diagnosed T2DM to alter long-term cardiovascular trajectories, even if immediate benefits are not statistically apparent during the initial trial phase.

Attending

UKPDS 33 established sulfonylureas and insulin as standard intensive therapies, but modern paradigms prioritize SGLT2 inhibitors and GLP-1 receptor agonists. How does the UKPDS framework of treating 'glucose' compare to the modern paradigm of treating 'cardio-renal risk', and how should we counsel stable patients still on legacy UKPDS regimens?

Key Response

UKPDS proved that lowering glucose reduces microvascular disease, but the legacy drugs caused weight gain and hypoglycemia without direct cardiovascular benefit. Modern agents offer direct cardio-renal protection and weight loss. Attendings must navigate the paradigm shift from purely glucocentric to organ-protective strategies, often deprescribing legacy drugs in favor of modern agents even if the patient's HbA1c is already at target.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In UKPDS 33, the conventional therapy group had a high rate of crossover to intensive therapy due to worsening hyperglycemia, yet the primary analysis was intent-to-treat (ITT). How does this crossover bias the estimation of the treatment effect on macrovascular outcomes, and what alternative causal inference methods could better estimate the true efficacy?

Key Response

High crossover in the conventional arm dilutes the glycemic separation between groups, biasing the ITT result toward the null. This makes it particularly difficult to detect outcomes requiring long-term glycemic separation. Researchers would explore per-protocol analyses, instrumental variables, or marginal structural models to account for time-varying confounding and treatment switching to isolate the true treatment effect.

Journal Editor

UKPDS 33 utilized an open-label design for a prolonged follow-up period. As a critical reviewer evaluating this methodology, what specific threats to validity regarding performance and detection biases would you flag, particularly concerning the evaluation of soft microvascular endpoints?

Key Response

In an open-label trial, patients and physicians know the treatment assignment, which can lead to unequal use of non-study co-interventions (like statins or antihypertensives) or heightened surveillance for complications in one arm. A seasoned reviewer would demand rigorous, blinded endpoint adjudication committees to ensure that subjective outcomes, like early neuropathy or retinopathy grading, were not influenced by knowledge of the glycemic control arm.

Guideline Committee

UKPDS 33 is the foundational evidence for the ADA/EASD recommendation targeting an HbA1c of <7.0% to prevent microvascular complications. As modern guidelines increasingly endorse SGLT2 inhibitors and GLP-1 RAs for cardio-renal benefit independent of baseline HbA1c, should the UKPDS-derived <7.0% target remain the primary quality metric, or should guidelines pivot toward an organ-protection prescribing metric?

Key Response

While UKPDS firmly established the <7.0% target for microvascular risk reduction, modern guidelines emphasize prescribing specific drug classes for mortality benefit regardless of A1c. The committee must weigh whether maintaining strict A1c metrics might inadvertently encourage the use of older, hypoglycemia-inducing agents just to 'hit a number', rather than prioritizing the initiation of life-prolonging, disease-modifying therapies.

Clinical Landscape

Noteworthy Related Trials

2008

ACCORD Trial

n = 10,251 · NEJM

Tested

Intensive glucose control (target HbA1c < 6.0%)

Population

T2DM patients with high CV risk

Comparator

Standard glucose control (target HbA1c 7.0-7.9%)

Endpoint

Nonfatal MI, nonfatal stroke, or CV death

Key result: Intensive therapy was discontinued prematurely due to higher all-cause mortality, with no significant reduction in major cardiovascular events.

2008

ADVANCE Trial

n = 11,140 · NEJM

Tested

Intensive glucose control (target HbA1c < 6.5%)

Population

T2DM patients with high CV risk

Comparator

Standard glucose control

Endpoint

Composite of major macrovascular and microvascular events

Key result: Intensive control reduced the incidence of major microvascular events, primarily driven by a reduction in nephropathy, with no significant effect on macrovascular outcomes.

2009

VADT Trial

n = 1,791 · NEJM

Tested

Intensive glucose control

Population

Veterans with poorly controlled T2DM

Comparator

Standard glucose control

Endpoint

Time to first major cardiovascular event

Key result: Intensive glucose control did not significantly reduce the rate of major cardiovascular events or death but did increase the risk of severe hypoglycemia.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis